https://www.selleckchem.com/products/fx-909.html
27 cases/1000 person-years). The AE and ADR incidences were 26.0% and 5.3%, respectively. The incidence of hypoglycemia was 0.6%. No significant changes in body weight occurred and mean change in HbA1c from baseline at final assessment was -0.74 ± 1.41% (p less then 0.0001).Conclusions In real-world clinical settings, vildagliptin was well tolerated, with similar profiles as previously reported.Aim To ascertain the clinical profile and management of edoxaban in clinical practice. Materials methods Prospective, noninterventional pos
Like
Comment
Share
